Streamline Health® To Report Fourth Quarter and Fiscal Year 2021 Financial Performance and Provide Corporate Update

Atlanta, GA, April 20, 2022 (GLOBE NEWSWIRE) —


Streamline Health Solutions, Inc.


(“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced that it will release its financial results for the three and twelve month periods ended January 31, 2022 on Wednesday, April 27, 2022 after the close of the financial markets.

The Company will conduct a conference call on Thursday, April 28, 2022 at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291.

A replay of the conference call will be available from Thursday, April 28, 2022 at 12:00 PM ET to Thursday, May 5, 2022 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13724715. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.

About Streamline

Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.

Company Contact 

Jacob Goldberger
Director, Investor Relations and FP&A
303-887-9625
[email protected]



Mercer International Inc.’s climate targets validated by the Science Based Targets initiative

NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) — Mercer International Inc. (“Mercer” or the “Company”) (Nasdaq: MERC) announced its 35% Greenhouse Gas reduction target by 2030 has been approved by the Science Based Targets initiative (SBTi) as consistent with the levels required to meet the goals of the Paris Agreement. The approval formally recognizes Mercer as a leading company and the first in Canada and one of the first North American companies in the forest and paper products sector with approved targets.

As disclosed by SBTi, Mercer’s commitment is to reduce Scope 1 GHG emissions by 35% per tonne of pulp by 2030 from a 2019 base year. In addition, we are also committing to reducing absolute Scope 2 and Scope 3 GHG emissions by 35% by 2030 from a 2019 base year. These targets are consistent with reductions required to keep warming to well below 2°C.

“We believe SBTi is recognized as the most reputable standard to validate climate targets, and this recognition provides clarity and confidence in our 2050 pathway to net-zero emissions and a more sustainable future,” said David Ure, Senior Vice President and CFO. He went on to state, “We look forward to continued collaboration with our customers and supply chain with a common purpose to reduce greenhouse gas and our carbon footprint.”

SBTi helps companies establish science-based targets to reduce greenhouse gas emissions and transform business operations to fit the future low-carbon economy. Targets adopted to reduce greenhouse gas (GHG) emissions are considered to be “science-based” if they are in line with what the latest available climate science says is necessary to meet the goals of the Paris Agreement – to limit global warming to well below 2°C above pre-industrial levels and pursue efforts to limit warming to 1.5°C.

SBTi is a collaboration between CDP, United Nations Global Compact (UNGC), World Resources Institute (WRI), World Wide Fund for Nature (WWF) and one of the We Mean Business Coalition commitments.

About Us

Mercer International Inc. is a global forest products company with operations in Germany, the USA, and Canada with a consolidated annual production capacity of 2.3 million tonnes of pulp and 550 million board feet of lumber, and 140 thousand cubic meters of CLT. To obtain further information on the company, please visit its website at https://www.mercerint.com.

The preceding includes forward-looking statements which involve known and unknown risks and uncertainties which may cause our actual results in future periods to differ materially from forecasted results. Words such as “expects”, “anticipates”, “are optimistic that”, “projects”, “intends”, “designed”, “will”, “believes”, “estimates”, “may”, “could” and variations of such words and similar expressions are intended to identify such forward‐looking statements. Among those factors which could cause actual results to differ materially are the following: the highly cyclical nature of our business, raw material costs, our level of indebtedness, competition, foreign exchange and interest rate fluctuations, our use of derivatives, expenditures for capital projects, environmental regulation and compliance, disruptions to our production, market conditions and other risk factors listed from time to time in our SEC reports.

APPROVED BY:

Jimmy S.H. Lee
Executive Chairman
(604) 684-1099

David M. Gandossi, FCPA, FCA
Chief Executive Officer
(604) 684-1099

Contact

If you would like more information, please contact:

Bill Adams
Vice President, Sustainability & Innovation
(604) 891-2617



Rigetti Hires Eric Ostby as Vice President of Product

Berkeley, CA, April 20, 2022 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (“Rigetti” or “the Company”) (NASDAQ:RGTI), a pioneer in hybrid quantum-classical computing systems, today announced the addition of Eric Ostby as Vice President of Product, effective April 12, 2022.

Ostby will lead Rigetti QCS™ product and platform development to advance the Company’s Quantum Computing as a Service (QCaaS) business in the public and private sectors. Ostby brings a wealth of experience in product leadership, most recently as Senior Product Manager for Quantum Computing at Google where he played a key role in the demonstration of quantum supremacy.

“Eric has a unique blend of technical knowledge in quantum computing, product leadership, and hands-on strategy and M&A experience. I’m thrilled to add him to our deep and talented team,” said Chad Rigetti, founder and CEO of Rigetti.

Rigetti recently launched its 80-qubit Aspen-M quantum computer on QCS and Amazon Braket, with the system available in private preview on Microsoft Azure. Ostby will help Rigetti capitalize on the expected expansion of commercial market opportunities to serve customers exploring a variety of high value business applications.

“I am thrilled to join Rigetti to lead and grow the QCS product function, and collaboratively take Rigetti’s full-stack quantum computing product to the next level,” Ostby said. His role will fall under the Company’s broader QCS organization led by Senior Vice President David Rivas. Ostby adds: “I look forward to working alongside Rigetti’s talented teams, partners, and customers as we develop quantum native applications today that will change how we work and live in the future.”

Ostby has over a decade of experience in strategy development and product management at Google, Ingram Micro, and Boston Consulting Group. His most recent work at Google included serving as the Product Lead for their quantum computing service and hardware development teams. Ostby holds a B.S. in Electrical Engineering from the University of Minnesota, and an M.S. and Ph.D. in Electrical Engineering from Caltech. 

About Rigetti

Rigetti is a pioneer in full-stack quantum computing. The Company has operated quantum computers over the cloud since 2017 and serves global enterprise, government and research clients through its Rigetti Quantum Cloud Services platform. The Company’s proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. Rigetti has developed the industry’s first multi-chip quantum processor for scalable quantum computing systems. The Company designs and manufactures its chips in-house at Fab-1, the industry’s first dedicated and integrated quantum device manufacturing facility. Rigetti was founded in 2013 by Chad Rigetti and today employs more than 160 people with offices in the United States, U.K. and Australia. Learn more at www.rigetti.com.

Cautionary Language Concerning Forward-Looking Statements
 

Certain statements in this communication may be considered forward-looking statements, including but not limited to, achieving quantum advantage; driving commercial growth and adoption of Rigetti’s quantum-computing-as-a-service business and Rigetti’s partnerships with public cloud providers and government agencies; driving future revenue growth; and other statements that are not historical facts. Forward-looking statements generally relate to future events and can be identified by terminology such as “pro forma,” “may,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential,” “pursue,” “anticipate” or “continue,” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Rigetti and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: Rigetti’s ability to achieve milestones, technological advancements, including with respect to its roadmap, help unlock quantum computing, and develop practical applications; the potential of quantum computing; the success of Rigetti’s partnerships and collaborations; Rigetti’s ability to accelerate its development of multiple generations of quantum processors; the outcome of any legal proceedings that may be instituted against Rigetti or others with respect to its business combination with Supernova Partners Acquisition Company II, Ltd. (the “Business Combination”) or other matters; the ability to meet stock exchange listing standards; the risk that the Business Combination disrupts current plans and operations of Rigetti; the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of Rigetti to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; costs related to the Business Combination and operating as a public company; changes in applicable laws or regulations; the possibility that Rigetti may be adversely affected by other economic, business, or competitive factors; Rigetti’s estimates of expenses and profitability; the evolution of the markets in which Rigetti competes; the ability of Rigetti to execute on its technology roadmap; the ability of Rigetti to implement its strategic initiatives, expansion plans and continue to innovate its existing services; the impact of the COVID-19 pandemic on Rigetti’s business; the expected use of proceeds of the Business Combination; the sufficiency of Rigetti’s cash resources; unfavorable conditions in Rigetti’s industry, the global economy or global supply chain, including financial and credit market fluctuations, international trade relations, political turmoil, natural catastrophes, warfare (such as the conflict involving Russia and Ukraine), and terrorist attacks; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration on Form S-4, the Company’s Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 7, 2022, and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements other than as required by applicable law. The Company does not give any assurance that it will achieve its expectations.

 

Attachments



Lauren Rugani
Rigetti Computing, Inc.
[email protected]

Polly Pearson
Investor Relations
[email protected]

CDK Global, Inc. Announces Cash Tender Offers and Consent Solicitations for Its 4.500% Senior Notes due 2024, 4.875% Senior Notes due 2027 and 5.250% Senior Notes due 2029

HOFFMAN ESTATES, Ill., April 20, 2022 (GLOBE NEWSWIRE) — CDK Global, Inc. (Nasdaq: CDK) (“CDK” or the “Company”), a leading automotive retail technology company, today announced that it has commenced tender offers (the “Tender Offers”) to purchase for cash any and all of its issued and outstanding 4.500% Senior Notes due 2024 (the “2024 Notes”), 4.875% Senior Notes due 2027 (the “2027 Notes”) and 5.250% Senior Notes due 2029 (the “2029 Notes” and, together with the 2024 Notes and the 2027 Notes, the “Notes”). In conjunction with the Tender Offers, CDK is soliciting consents (the “Solicitations”) to the adoption of proposed amendments to each of the indentures governing the Notes (together, the “Indentures”) to, among other things, eliminate any obligation to make a Change of Control Offer (as defined in the applicable Indenture), substantially all of the other restrictive covenants and certain events of default and other provisions (the “Proposed Amendments”).

The pricing terms for the Tender Offers and Solicitations are set forth below.

CUSIP Nos. ISIN Nos. Outstanding Principal
Amount
Title of Security Purchase
Price(1)(2)
Consent
Payment
(1)(2)
Total
Consideration(1)
12508EAD3 US12508EAD31   $500,000,000 4.500% Senior Notes due
2024(3)
  $1,006.25   $30.00   $1,036.25
12508EAF8 US12508EAF88   $600,000,000 4.875% Senior Notes due
2027
  $982.50   $30.00   $1,012.50
12508EAJ0
U12227AD3
US12508EAJ01
USU12227AD34
  $500,000,000 5.250% Senior Notes due
2029
  $982.50   $30.00   $1,012.50

(1)    Per $1,000 principal amount of Notes and excluding Accrued Interest (as defined below), which will be paid in addition to the Total Consideration or Purchase Price, as applicable, up to the payment date.
(2)    Included in Total Consideration.
(3)    Original interest rate. Pursuant to the terms of the 2024 Notes, the interest rate adjusts from time to time and is currently 5.000%.

CDK is undertaking the Tender Offers and the Solicitations in connection with the Agreement and Plan of Merger, dated as of April 7, 2022, by and among Central Parent LLC, a Delaware limited liability company (the “Acquiror”), Central Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of the Acquiror (“Merger Sub”), and the Company, as amended from time to time, pursuant to which Merger Sub will be merged with and into CDK, with CDK surviving such merger as a wholly-owned subsidiary of the Acquiror (such transaction, the “Acquisition”). The Acquiror is an affiliate of Brookfield Asset Management Inc. and Brookfield Capital Partners VI L.P. CDK anticipates that the Acquisition will be completed in the third quarter of 2022. Neither the completion of the Tender Offers nor the adoption of the Proposed Amendments is a condition to the consummation of the Acquisition or to the financing of the Acquisition. For more information regarding the Proposed Amendments, please refer to the Offer to Purchase and Consent Solicitation Statement, dated April 20, 2022.

Each Tender Offer is currently scheduled to expire at 12:00 midnight, New York City time, at the end of the day on May 17, 2022, unless extended (such time and date, as the same may be extended with respect to a Tender Offer, the “Expiration Date”). Holders of Notes must validly tender (and not validly withdraw) their Notes and validly deliver (and not validly revoke) their corresponding consents at or prior to 5:00 P.M., New York City time, on May 3, 2022, unless extended (such time and date, as the same may be extended with respect to a Tender Offer, the “Consent Time”), to be eligible to receive the Total Consideration per $1,000 principal amount of Notes tendered, which includes a Consent Payment per $1,000 principal amount of Notes tendered, as set forth in the table above. Holders who tender their Notes after the applicable Consent Time and on or prior to the applicable Expiration Date will be eligible to receive the Purchase Price per $1,000 principal amount of Notes tendered set forth in the table above, but not the Consent Payment. The Total Consideration (including the Consent Payment) will only be payable to holders of Notes who validly tender and do not validly withdraw their Notes, and who validly deliver and do not validly revoke the corresponding consent at or prior to the applicable Consent Time, and whose Notes are accepted for purchase. Tendered Notes may be withdrawn and consents may be revoked at or prior to the earlier of the applicable Consent Time and such time and date as we receive the applicable Requisite Consent (as defined below) (such time and date, as the same may be extended with respect to a Tender Offer, the “Withdrawal Deadline”) but may not thereafter be withdrawn or revoked. CDK may extend the Consent Time for a Tender Offer without extending the Withdrawal Deadline for such Tender Offer. A holder of Notes cannot deliver a consent without tendering its corresponding Notes or tender its Notes without delivering a corresponding consent.

Consummation of the Acquisition will constitute a Change of Control under each Indenture, which will result in a Change of Control Triggering Event (as defined in the applicable Indenture) with respect to a series of Notes if a Rating Event (as defined the applicable Indenture) with respect to such series of Notes also occurs. CDK believes that it is likely that a Rating Event will occur with respect to each series of the Notes in connection with the Acquisition, which would result in a Change of Control Triggering Event upon the consummation of the Acquisition. Following a Change of Control Triggering Event, each Indenture requires CDK to make a Change of Control Offer to purchase for cash all of the outstanding applicable Notes validly tendered by any holder upon the terms described in such Indenture, including at a price equal to 101% of the principal amount of the applicable Notes, plus accrued and unpaid interest, if any, to the purchase date. If a Tender Offer is consummated and the Proposed Amendments become operative, the Notes subject to such Tender Offer that remain outstanding will not benefit from any of the restrictive covenants that are eliminated by the adoption of the Proposed Amendments and the Acquisition will not trigger the requirement that the Company make a Change of Control Offer under the applicable Indenture.

In each Tender Offer, upon the terms and conditions described in the Offer to Purchase and Consent Solicitation Statement, CDK will, promptly following the applicable Expiration Date, accept for purchase all Notes validly tendered on or prior to the applicable Expiration Date with respect to a Tender Offer (the “Acceptance Date”). Payment for Notes so accepted for purchase will be made promptly following the applicable Acceptance Date with respect to a Tender Offer (the “Settlement Date”). Payment for the Notes so accepted for purchase will be made by the deposit of immediately available funds by CDK with D.F. King & Co., Inc., promptly thereafter. CDK reserves the right to waive any and all conditions of the Tender Offers, in whole or in part.

In addition to the Total Consideration or Purchase Price, as applicable, holders of Notes tendered and accepted for payment will receive accrued and unpaid interest on such Notes at the rate in effect on the date of the Offer to Purchase and Consent Solicitation Statement from the last interest payment date for the Notes up to, but not including, the applicable Settlement Date (“Accrued Interest”), which CDK expects to coincide with the closing of the Acquisition. As CDK intends for the Settlement Date of each Tender Offer to coincide with the closing of the Acquisition, CDK intends to extend the applicable Expiration Date and, consequently, the applicable Acceptance Date and the applicable Settlement Date for each Tender Offer in order for this to occur.

The consummation of a Tender Offer (including to pay the Consent Payment) is conditioned upon (1) the receipt of consents at or prior to the applicable Consent Time from holders of at least a majority of the outstanding aggregate principal amount of the Notes in such Tender Offer (the “Requisite Consent”), (2) the valid execution of a supplemental indenture to the applicable Indenture (collectively, the “Supplemental Indentures”), (3) the receipt by CDK of net proceeds from a financing on terms and conditions satisfactory to CDK, which will be sufficient to fund the Total Consideration in respect of all applicable Notes (regardless of the actual amount of any Notes tendered) and estimated fees and expenses relating to such Tender Offer and Solicitation, (4) the consummation of the Acquisition and (5) satisfaction of certain other customary conditions. CDK’s obligation to accept any consent validly delivered in connection with a Solicitation is conditioned upon (1) the receipt of the Requisite Consent for such Solicitation and (2) satisfactions of certain other customary conditions. In each case, CDK may waive any of or all of these conditions at its discretion. Holders who validly tender and do not validly withdraw their Notes prior to the Withdrawal Deadline and who validly deliver and do not validly revoke the corresponding consent at or prior to the applicable Consent Time and whose Notes are accepted for purchase will not be paid the Total Consideration (including the Consent Payment) or the Purchase Price, as applicable, until the applicable Settlement Date, and CDK’s obligation to accept Notes for purchase and pay such amounts is subject to the conditions described above. In addition, the Proposed Amendments to each Indenture will be effected by the applicable Supplemental Indenture, which is to be executed at such time as CDK has received the Requisite Consent with respect thereto. Each Supplemental Indenture will become effective when such Supplemental Indenture is executed and delivered by the parties thereto, but the Proposed Amendments will not become operative unless the Notes issued thereunder tendered at or prior to the applicable Consent Time are accepted for purchase on the applicable Acceptance Date.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders or consents with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful. The Tender Offers will only be made pursuant to the terms of the Offer to Purchase and Consent Solicitation Statement.

The complete terms and conditions of the Tender Offers and Solicitations are set forth in an Offer to Purchase and Consent Solicitation Statement that is being sent to holders of the Notes. Holders are urged to read the tender offer documents carefully before making any decision with respect to the Tender Offers and the Solicitations. Holders of Notes must make their own decisions as to whether to tender any or all of their Notes and provide the related consent.

Holders may obtain copies of the Offer to Purchase and Consent Solicitation Statement from the Information Agent and Tender Agent for the Tender Offers, D.F. King & Co., Inc., at (212) 269-5550 (collect, for banks and brokers only) and (888) 540-8736 (toll free).

Credit Suisse Securities (USA) LLC is the Dealer Manager for the Tender Offers and Solicitation Agent for the Solicitations. Questions regarding the Tender Offers and Solicitations may be directed to Credit Suisse Securities (USA) LLC at (800) 820-1653 (toll free) and (212) 325-2476 (collect).

None of CDK, the Dealer Manager and Solicitation Agent, the Information Agent and Tender Agent or any other person makes any recommendation as to whether holders of Notes should tender their Notes or provide the related consents, and no one has been authorized to make such a recommendation.

About CDK Global, Inc.

With approximately $2 billion in revenues, CDK Global (NASDAQ: CDK) is a leading provider of retail technology and software as a service (SaaS) solutions that help dealers and auto manufacturers run their businesses more efficiently, drive improved profitability and create frictionless purchasing and ownership experiences for consumers. Today, CDK serves over 15,000 retail locations in North America. For more information, visit cdkglobal.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking statements. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. By their nature, forward-looking statements involve risks and uncertainty because they relate to events and depend on circumstances that will occur in the future, and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements include, among other things, statements about the ability of the parties to complete the proposed transaction and the expected timing of completion of the proposed transaction; as well as any assumptions underlying any of the foregoing.

The following are some of the factors that could cause actual future results to differ materially from those expressed in any forward-looking statements: (i) uncertainties as to the timing of, and the Company’s ability to complete, the Tender Offers and Solicitations, (ii) uncertainties as to the timing of the equity tender offer and the merger; (iii) the risk that the proposed transaction may not be completed in a timely manner or at all; (iv) uncertainties as to the percentage of the Company’s stockholders tendering their shares of common stock in the equity tender offer; (v) the possibility that competing offers or acquisition proposals for the Company will be made; (vi) the possibility that any or all of the various conditions to the consummation of the tender offer or the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (vii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, including in circumstances that would require the Company to pay a termination fee or other expenses; (viii) the effect of this announcement or pendency of the proposed transaction on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; (ix) risks related to diverting management’s attention from the Company’s ongoing business operations; (x) the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; and (xi) other factors as set forth from time to time in the Company’s filings with the SEC, including its annual report on Form 10-K for the fiscal year ended June 30, 2021 and any subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are based on information currently available to the Company, and the Company expressly disclaims any intent or obligation to update, supplement or revise publicly these forward-looking statements except as required by law.

Media Contacts:


Tony Macrito
630.805.0782
[email protected]

Investor Relations Contact:

Reuben Gallegos
847.542.3254
[email protected]



Lincoln Electric Board Declares Dividend

CLEVELAND, April 20, 2022 (GLOBE NEWSWIRE) — Lincoln Electric Holdings, Inc., (Nasdaq: LECO) announced today that its Board of Directors has declared a quarterly cash dividend of $0.56 per common share, payable July 15, 2022 to shareholders of record as of June 30, 2022.


Business

Lincoln Electric is the world leader in the engineering, design, and manufacturing of advanced arc welding solutions, automated joining, assembly and cutting systems, plasma and oxy-fuel cutting equipment, and has a leading global position in brazing and soldering alloys. Lincoln is recognized as the Welding Expert™ for its leading material science, software development, automation engineering, and application expertise, which advance customers’ fabrication capabilities to help them build a better world. Headquartered in Cleveland, Ohio, Lincoln has 56 manufacturing locations in 19 countries and a worldwide network of distributors and sales offices serving customers in over 160 countries. For more information about Lincoln Electric and its products and services, visit the Company’s website at https://www.lincolnelectric.com.



Contact

Amanda Butler
Vice President, Investor Relations & Communications
Tel: 216.383.2534
Email: [email protected]

Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend

SHREVEPORT, La., April 20, 2022 (GLOBE NEWSWIRE) — Home Federal Bancorp, Inc. of Louisiana (the “Company”) (NASDAQ: HFBL), the holding company for Home Federal Bank, announced today that its Board of Directors at their meeting on April 20, 2022, declared a quarterly cash dividend of $0.10 per share on the Company’s common stock. The dividend is payable on May 16, 2022, to the shareholders of record at the close of business on May 2, 2022.

Home Federal Bancorp, Inc. of Louisiana is the holding company for Home Federal Bank which conducts business from its nine full-service banking offices and home office in northwest Louisiana. Additional information is available at www.hfb.bank.

Statements contained in this news release which are not historical facts may be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words like “believe,” “expect,” “anticipate,” “estimate” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could” or “may.” We undertake no obligation to update any forward-looking statements.

Contact:
Home Federal Bancorp, Inc. of Louisiana
James R. Barlow, Chairman of the Board, President and Chief Executive Officer
(318) 222-1145



Travere Therapeutics Announces Plan for Chief Financial Officer Transition

Laura Clague to step-down as CFO in August 2022 and retire in 2023

Chris Cline, Travere SVP of Investor Relations & Corporate Communications, to assume position of chief financial officer in August 2022

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief financial officer Laura Clague, CPA, will retire after serving in this role for the past seven years. Ms. Clague will step down from the CFO position in August 2022 and will remain employed by the Company in an advisory capacity into 2023 to facilitate a smooth transition. Chris Cline, CFA, the Company’s current senior vice president of investor relations and corporate communications and a member of the senior leadership team, has been named Ms. Clague’s successor as chief financial officer, to be effective in August 2022.

“On behalf of the Board and our Travere employees, I want to thank Laura for her unwavering dedication to our mission and for her many contributions over the past seven years to help establish Travere as a leader in the rare disease community,” said Eric Dube, Ph.D. president and chief executive officer of Travere Therapeutics. “Under Laura’s leadership, we have successfully grown our operations, developed an exceptional finance team and established a strong financial position that will enable us to continue advancing our pipeline of important potential new treatments, and prepare for commercial launches of sparsentan, if approved, beginning as early as the end of this year.”

Dr. Dube continued, “Chris has been an instrumental leader over the past seven years, and we are very pleased that he will be taking on the position of CFO. He brings an extensive track record of working with the investment community, deep institutional knowledge and a strategic vision which will be ideally suited for the CFO role as we enter a new phase of growth. We look forward to working closely with Chris to build upon our strong financial foundation and further our leadership position in the rare disease community.”

Mr. Cline brings more than 15 years of industry experience in investor relations, corporate communications, and financial strategy, planning and analysis to the chief financial officer position. Since joining Travere in 2014, Mr. Cline has been responsible for leading engagement with the investment community, as well as building a developed corporate communications infrastructure. He has served as a member of the Travere senior leadership team since 2019. Prior to Travere, Mr. Cline was a member of the global investor relations group at Elan Corporation, plc, and the financial planning and analysis group at Phase Forward. Mr. Cline is a CFA® charterholder and holds a degree in finance from the Williams College of Business at Xavier University.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Forward Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “may”, “might”, “believes”, “thinks”, “anticipates”, “plans”, “expects”, “intends” or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: the expected timing of the planned Chief Financial Officer transition and Ms. Clague’s retirement date; the ability of the Company’s financial position to enable the continued advancement of the Company’s pipeline of important potential new treatments, and preparations for commercial launches of sparsentan, if approved, and references to the potential timing thereof; and the ability for the Company to build upon its strong financial foundation and further its leadership position in the rare disease community. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the regulatory review and approval process, including the Subpart H accelerated approval pathway. Specifically, the Company faces the risk that sparsentan will not be approved for efficacy, safety, regulatory or other reasons, and for each of the Company’s programs, risk associated with enrollment of clinical trials for rare diseases and risk that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. The Company faces risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates; risk relating to the Company’s dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, and technological changes that may limit demand for the Company’s products. The Company faces additional risks associated with the potential impacts the COVID-19 pandemic may have on its business, including, but not limited to (i) the Company’s ability to continue its ongoing development activities and clinical trials, (ii) the timing of such clinical trials and the release of data from those trials, (iii) the Company’s and its suppliers’ ability to successfully manufacture its commercial products and product candidates, and (iv) the market for and sales of its commercial products. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other filings with the Securities and Exchange Commission.

Contact:
Nivi Nehra
Vice President, Corporate Communications
888-969-7879
[email protected]

 



CF Industries Holdings, Inc. Confirms Date and Time for First Quarter 2022 Results and Conference Call

CF Industries Holdings, Inc. Confirms Date and Time for First Quarter 2022 Results and Conference Call

DEERFIELD, Ill–(BUSINESS WIRE)–
CF Industries Holdings, Inc. (NYSE: CF) today confirmed that it will report its first quarter 2022 results after the market close on Wednesday, May 4, 2022. The company plans to host a conference call to discuss these results at 10:00 a.m. ET on Thursday, May 5, 2022.

Investors can access the call by dialing 866-374-5140 or 404-400-0571. The passcode is 75104576. The conference call also will be available live on the company’s website at www.cfindustries.com. Participants also may pre-register for the webcast on the company’s website. Please log-in or dial-in at least 10 minutes prior to the start time to ensure a connection. A replay of the webcast will be available through the company’s website at www.cfindustries.com.

About CF Industries Holdings, Inc.

At CF Industries, our mission is to provide clean energy to feed and fuel the world sustainably. With our employees focused on safe and reliable operations, environmental stewardship, and disciplined capital and corporate management, we are on a path to decarbonize our ammonia production network – the world’s largest – to enable green and blue hydrogen and nitrogen products for energy, fertilizer, emissions abatement and other industrial activities. Our nine manufacturing complexes in the United States, Canada, and the United Kingdom, an unparalleled storage, transportation and distribution network in North America, and logistics capabilities enabling a global reach underpin our strategy to leverage our unique capabilities to accelerate the world’s transition to clean energy. CF Industries routinely posts investor announcements and additional information on the Company’s website at www.cfindustries.com and encourages those interested in the Company to check there frequently.

Media

Chris Close

Director, Corporate Communications

847-405-2542 – [email protected]

Investors

Martin Jarosick

Vice President, Treasury and Investor Relations

847-405-2045 – [email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Other Manufacturing Environment Other Energy Manufacturing Alternative Energy Energy Other Natural Resources Agriculture Natural Resources

MEDIA:

Logo
Logo

RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. and RiverNorth Specialty Finance Corporation Announce Preferred Dividends

RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. and RiverNorth Specialty Finance Corporation Announce Preferred Dividends

WEST PALM BEACH, Fla.–(BUSINESS WIRE)–
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. and RiverNorth Specialty Finance Corporation are each pleased to announce the declaration of preferred dividends for the second quarter of 2022, as detailed below.

Ex Date

Record Date

Payable Date

May 2, 2022

May 3, 2022

May 16, 2022

Fund Name

Preferred Stock Series

NYSE

Distribution Per Share

RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.

4.375% Series A Cumulative Preferred Stock

OPPPRA

$0.27344

RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.

4.75% Series B Cumulative Preferred Stock

OPPPRB

$0.29688

RiverNorth Specialty Finance Corporation

5.875% Series A Term Preferred Stock

RMPL

$0.36719

About RiverNorth

RiverNorth Capital Management, LLC is an investment management firm founded in 2000. With $5.9 billion1 in assets under management as of February 28, 2022, RiverNorth specializes in opportunistic investment strategies in niche markets where the potential to exploit inefficiencies is greatest. RiverNorth is an institutional investment manager to registered funds, private funds and separately managed accounts.

The distributions were calculated based on the preferred shares Liquidation Preference of $25.00 per share and most current quarterly distribution rate per share of $0.27344 for RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.’s 4.375% Series A Cumulative Preferred Stock, $0.29688 for RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.’s 4.75% Series B Cumulative Preferred Stock, and $0.36719 for RiverNorth Specialty Finance Corporation’s 5.875% Series A Term Preferred Stock, respectively. Distributions may be paid from sources of income other than ordinary income, such as net realized short-term capital gains, net realized long-term capital gains and return of capital. The actual amounts and sources of the amounts for tax reporting purposes will depend upon each Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. If a distribution includes anything other than net investment income, the Fund provides a Section 19(a) notice of the best estimate of its distribution sources at that time. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholders’ 1099-DIV forms after the end of the year.

This data is for information only and should not be construed as an official tax form, nor should it be considered tax or investment advice. RiverNorth is not a tax advisor and investors should consult a tax professional for guidance regarding their specific tax situation. Please consult your legal or tax advisor.

Investors should consider the Fund’s investment objective, risks, charges and expenses carefully before investing. The prospectus should be read carefully before investing. For more information, please read the prospectus, call your financial professional or call 844.569.4750.

Investing in the Fund involves certain risks, including loss of principal, that are described in the “Risks” section of each Prospectus.

Member Firm ALPS Distributors Inc. ALPS and RiverNorth are not affiliated.

1Firm AUM reflects Managed Assets which includes the effects of leverage and investments in affiliated funds.

RiverNorth® is a registered trademark of RiverNorth Capital Management, LLC. DoubleLine® is a registered trademark of DoubleLine Capital LP.

©2000-2022 RiverNorth Capital Management, LLC. All rights reserved.

OPP000113

Investor Contact

Chris Lakumb, CFA, CAIA

312.445.2336

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Flowserve Announces Dates for First Quarter 2022 Financial Results

Flowserve Announces Dates for First Quarter 2022 Financial Results

DALLAS–(BUSINESS WIRE)–
Flowserve Corporation (NYSE: FLS), a leading provider of flow control products and services for the global infrastructure markets, today announced that it plans to release its results for the first quarter 2022 after the close of the New York Stock Exchange (NYSE) on Monday, May 2.

The following morning, on Tuesday, May 3, the company will hold its conference call with the financial community at 11 a.m. Eastern time. Scott Rowe, president and chief executive officer, and other members of management will present.

The earnings materials and webcast of the conference call can be accessed by shareholders and other interested parties at www.flowserve.com under the “Investor Relations” section.

About Flowserve

Flowserve Corp. is one of the world’s leading providers of fluid motion and control products and services. Operating in more than 50 countries, the company produces engineered and industrial pumps, seals and valves as well as a range of related flow management services. More information about Flowserve can be obtained by visiting the company’s Web site at www.flowserve.com.

Safe Harbor Statement: This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words or phrases such as “may,” “should,” “expects,” “could,” “intends,” “plans,” “anticipates,” “estimates,” “believes,” “forecasts,” “predicts” or other similar expressions are intended to identify forward-looking statements, which include, without limitation, earnings forecasts, statements relating to our business strategy and statements of expectations, beliefs, future plans and strategies and anticipated developments concerning our industry, business, operations and financial performance and condition.

The forward-looking statements included in this news release are based on our current expectations, projections, estimates and assumptions. These statements are only predictions, not guarantees. Such forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict. These risks and uncertainties may cause actual results to differ materially from what is forecast in such forward-looking statements, and include, without limitation, the following: the impact of the global outbreak of COVID-19 on our business and operations; a portion of our bookings may not lead to completed sales, and our ability to convert bookings into revenues at acceptable profit margins; changes in global economic conditions and the potential for unexpected cancellations or delays of customer orders in our reported backlog; our dependence on our customers’ ability to make required capital investment and maintenance expenditures; if we are not able to successfully execute and realize the expected financial benefits from our strategic transformation and realignment initiatives, our business could be adversely affected; risks associated with cost overruns on fixed-fee projects and in taking customer orders for large complex custom engineered products; the substantial dependence of our sales on the success of the oil and gas, chemical, power generation and water management industries; the adverse impact of volatile raw materials prices on our products and operating margins; economic, political and other risks associated with our international operations, including military actions, trade embargoes, epidemics or pandemics or changes to tariffs or trade agreements that could affect customer markets, particularly North African, Russian and Middle Eastern markets and global oil and gas producers, and non-compliance with U.S. export/re-export control, foreign corrupt practice laws, economic sanctions and import laws and regulations; increased aging and slower collection of receivables, particularly in Latin America and other emerging markets; our exposure to fluctuations in foreign currency exchange rates, including in hyperinflationary countries such as Venezuela and Argentina; our furnishing of products and services to nuclear power plant facilities and other critical processes; potential adverse consequences resulting from litigation to which we are a party, such as litigation involving asbestos-containing material claims; expectations regarding acquisitions and the integration of acquired businesses; our relative geographical profitability and its impact on our utilization of deferred tax assets, including foreign tax credits; the potential adverse impact of an impairment in the carrying value of goodwill or other intangible assets; our dependence upon second-party suppliers whose failure to perform timely could adversely affect our business operations; the highly competitive nature of the markets in which we operate; environmental compliance costs and liabilities; potential work stoppages and other labor matters; access to public and private sources of debt financing; our inability to protect our intellectual property in the U.S., as well as in foreign countries; obligations under our defined benefit pension plans; our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud; the recording of increased deferred tax asset valuation allowances in the future or the impact of tax law changes on such deferred tax assets could affect our operating results; our information technology infrastructure could be subject to service interruptions, data corruption, cyber-based attacks or network security breaches, which could disrupt our business operations and result in the loss of critical and confidential information; ineffective internal controls could impact the accuracy and timely reporting of our business and financial results; and other factors described from time to time in our filings with the Securities and Exchange Commission.

All forward-looking statements included in this news release are based on information available to us on the date hereof, and we assume no obligation to update any forward-looking statement.

The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). However, management believes that non-GAAP financial measures which exclude certain non-recurring items present additional useful comparisons between current results and results in prior operating periods, providing investors with a clearer view of the underlying trends of the business. Management also uses these non-GAAP financial measures in making financial, operating, planning and compensation decisions and in evaluating the Company’s performance. Throughout our materials we refer to non-GAAP measures as “Adjusted.” Non-GAAP financial measures, which may be inconsistent with similarly captioned measures presented by other companies, should be viewed in addition to, and not as a substitute for, the Company’s reported results prepared in accordance with GAAP.

Investor Contacts:

Jay Roueche, Vice President, Investor Relations & Treasurer, (972) 443-6560

Mike Mullin, Director, Investor Relations, (972) 443-6636

Media Contact:

Lars Rosene, Vice President, Corporate Communications & Public Affairs, (972) 443-6644

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Engineering Other Energy Oil/Gas Manufacturing Energy Other Manufacturing

MEDIA:

Logo
Logo